Fusion Pharmaceuticals Inc.
METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER
Last updated:
Abstract:
Provided herein are the use of FGFR3 inhibitors and taxanes to treat solid and hematologic cancers, as well as compositions and kits comprising an FGFR3 inhibitor and a taxane.
Status:
Application
Type:
Utility
Filling date:
27 Apr 2020
Issue date:
1 Oct 2020